• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY: TAK )

    13.05 -0.04 (-0.34%)
    Streaming Delayed Price Updated: 11:24 AM EST, Dec 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

    < Previous 1 2
    ...
    6 7 8 9 10 11 12 13 14
    ...
    17 18 Next >
    Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26
    CNBC The Aviation Sector Is Slammed By Sky-High Rents 
    Via Benzinga
    After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
    Via Benzinga
    Recap Of Monday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
    Shares hit their lowest point since November on the FDA's decision in HAE. 
    Via Investor's Business Daily
    Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
    Via Benzinga
    Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Peering Into Takeda Pharmaceutical's Recent Short Interest
    Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold... 
    Via Benzinga
    Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
    BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome... 
    Via Benzinga
    Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
    Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could... 
    Via FinancialNewsMedia
    Exposures COVID-19 Product Safety
    Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
    Via Benzinga
    Peering Into Takeda Pharmaceutical's Recent Short Interest
    Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which... 
    Via Benzinga
    Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
    Upgrades 
    Via Benzinga
    Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful
    Via Benzinga
    Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Looking Into Takeda Pharmaceutical's Recent Short Interest
    Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which... 
    Via Benzinga
    Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
    Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. 
    Via Benzinga
    Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    As Health Problems Mount Patients Welcome New Treatments
    Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,... 
    Via FinancialNewsMedia
    Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act'
    Moderna tested a bivalent booster, which targets two Covid strains in one shot. 
    Via Investor's Business Daily
    Quant Ratings Updated on 66 Stocks
    Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10. 
    Via InvestorPlace
    Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
    Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,... 
    From Moderna, Inc.
    Via AccessWire
    Exposures COVID-19
    Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Current Report: Takeda Pharmaceutical
    Takeda’s price per share was $14.31 as of yesterday's market close. One year ago its price was $17.20. 
    Via Talk Markets
    < Previous 1 2
    ...
    6 7 8 9 10 11 12 13 14
    ...
    17 18 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.